Balimek (binimetinib)
- Region
- 🇪🇺 EU
- Active substance
- binimetinib
- Company
- Pierre Fabre Médicament
- Status
- Application withdrawn
- Therapeutic area
- Melanoma
- Application
- EMEA/H/C/004052
- ATC
- L01XE
- Official record
- www.ema.europa.eu
Indication
Treatment of unresectable or metastatic melanoma. Treatment of unresectable melanoma, with NRA Q61 mutation.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Mektovi Authorised · Pierre Fabre Medicament
Follow Balimek
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.